| Recruiting | Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer Small Cell Lung Cancer (SCLC) | Phase 2 | 2026-02-01 |
| Recruiting | Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer Advanced Cancer, Metastatic Cancer | N/A | 2025-07-01 |
| Active Not Recruiting | Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC NSCLC | Phase 2 | 2023-12-07 |
| Withdrawn | Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | 2022-10-01 |
| Recruiting | A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer Endometrial Cancer | Phase 1 / Phase 2 | 2021-10-20 |
| Active Not Recruiting | Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide Metastatic Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer | Phase 2 | 2021-08-17 |
| Active Not Recruiting | CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell L Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer | Phase 2 | 2021-03-10 |
| Active Not Recruiting | Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnose Myeloma, Multiple | Phase 2 | 2020-10-21 |
| Completed | Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma | Phase 1 | 2019-08-29 |
| Terminated | Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis | Phase 1 | 2019-06-27 |
| Active Not Recruiting | Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma Mantle Cell Lymphoma, B Cell Lymphoma | Phase 2 | 2018-09-11 |
| Completed | Atezolizumab Immunotherapy in Patients With Advanced NSCLC Carcinoma, Non-Small-Cell Lung | Phase 2 | 2017-11-01 |
| Completed | Electronic Patient Reporting of Symptoms During Cancer Treatment Metastatic Cancer | N/A | 2017-10-30 |
| Active Not Recruiting | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer | Phase 3 | 2017-06-21 |
| Terminated | Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer Small Cell Lung Cancer | Phase 2 | 2017-05-20 |
| Completed | A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer Prostate Cancer | Phase 3 | 2017-03-06 |
| Active Not Recruiting | Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS DCIS, Ductal Carcinoma in Situ | N/A | 2017-02-22 |
| Completed | Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT) | N/A | 2016-12-13 |
| Terminated | A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer Non-Small-Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Nonsmall Cell Lung Cancer | Phase 2 | 2016-12-01 |
| Completed | Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC Non-Small Cell Lung Cancer | Phase 2 | 2016-03-01 |
| Completed | Optimizing the Effectiveness of Routine Post-treatment Surveillance in Prostate Cancer Survivors Cancer of Prostate, Cancer of the Prostate, Prostate Cancer | — | 2016-02-01 |
| Active Not Recruiting | PALbociclib CoLlaborative Adjuvant Study Breast Cancer | Phase 3 | 2015-08-01 |